利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

338 条记录 (耗时 0.044 秒)

    WHSC1 AND WHSC1L1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
    81.
    发明申请
    WHSC1 AND WHSC1L1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 审中-公开
    WHSC1和WHSC1L1用于靶向治疗癌症和诊断基因

    公开(公告)号：US20130137748A1

    公开(公告)日：2013-05-30

    申请号：US13576917

    申请日：2011-02-02

    申请人： Ryuji Hamamoto ,  Yusuke Nakamura ,  Takuya Tsunoda

    发明人： Ryuji Hamamoto ,  Yusuke Nakamura ,  Takuya Tsunoda

    IPC分类号： C12N15/113 ,  C12Q1/02 ,  G01N33/53

    CPC分类号： C12N15/1137 ,  A61K31/713 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/53

    摘要： Objective methods for diagnosing a predisposition to developing cancer, for example, bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma, are described herein. In one embodiment, the diagnostic method involves determining an expression level of a WHSC1 or WHSC1L1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of WHSC1 or WHSC1L1 associated disease, such as a cancer, e.g., bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of WHSC1 or WHSC1L1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions including them. Also, disclosed are methods of identifying substances for treating or/and preventing lung cancer, using as an index their effect on expression of a WHSC1 or WHSC1L1 gene, or a biological activity of a WHSC1 or WHSC1L1 polypeptide.

    摘要翻译： 用于诊断发展中癌症的倾向的客观方法，例如膀胱癌，乳腺癌，胆管细胞癌，CML，食管癌，HCC，NSCLC，SCLC，骨肉瘤，胰腺癌，前列腺癌，肾细胞癌，软组织肿瘤和淋巴瘤 ，在此描述。 在一个实施方案中，诊断方法包括确定WHSC1或WHSC1L1基因的表达水平。 本发明还提供筛选用于治疗WHSC1或WHSC1L1相关疾病的治疗剂的方法，例如癌症，例如膀胱癌，乳腺癌，胆管细胞癌，CML，食管癌，HCC，NSCLC，SCLC，骨肉瘤 ，胰腺癌，前列腺癌，肾细胞癌，软组织肿瘤和淋巴瘤。 本发明还提供抑制细胞生长和治疗或减轻WHSC1或WHSC1L1相关疾病症状的方法。 本发明还包括产物，包括双链分子和编码它们的载体以及包括它们的组合物。 此外，公开了用于鉴定用于治疗或/和预防肺癌的物质的方法，以其对WHSC1或WHSC1L1基因表达的影响或WHSC1或WHSC1L1多肽的生物活性的指标。

    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME
    82.
    发明申请
    HJURP PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    HJURP肽和疫苗，包括它们

    公开(公告)号：US20130064840A1

    公开(公告)日：2013-03-14

    申请号：US13583195

    申请日：2011-03-10

    申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： A61K39/00 ,  C12N15/11 ,  C12N5/0783 ,  C12N15/63 ,  C12N15/85 ,  C12N5/0784 ,  C07K16/00 ,  C07K7/06 ,  A61P35/00

    CPC分类号： C07K14/4748 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/18

    摘要： Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

    摘要翻译： 衍生自SEQ ID NO：50的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗的上下文，更具体地，本文描述了癌症疫苗。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸序列被取代，缺失，添加或插入，只要这些修饰形式保留原始序列的必需细胞毒性T细胞诱导性 。 还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。 本发明的肽，核酸，药物，物质和组合物特别用于治疗癌症和肿瘤，包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌， 食管癌，扩散型胃癌，肝癌，NSCLC，淋巴瘤，骨肉瘤，卵巢癌，胰腺癌，前列腺癌，肾癌，SCLC，软组织肿瘤和睾丸肿瘤。

    Genes and polypeptides relating to human colon cancers
    86.
    发明授权
    Genes and polypeptides relating to human colon cancers 有权
    与人结肠癌相关的基因和多肽

    公开(公告)号：US07425612B2

    公开(公告)日：2008-09-16

    申请号：US10916064

    申请日：2004-08-10

    申请人： Yusuke Nakamura ,  Yoichi Furukawa ,  Hideaki Tahara ,  Takuya Tsunoda

    发明人： Yusuke Nakamura ,  Yoichi Furukawa ,  Hideaki Tahara ,  Takuya Tsunoda

    IPC分类号： C07K14/00 ,  C07K5/00

    CPC分类号： C07K14/47 ,  C07K14/4748

    摘要： The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease.

    摘要翻译： 本申请提供了在结肠直肠癌中表达显着升高的新型人基因RNF43，以及与相应的非癌组织相比，胃癌中其表达显着升高的CXADRL1和GCUD1。 由该基因编码的基因和多肽可用于例如细胞增殖性疾病的诊断，以及用于开发针对该疾病的药物的靶分子。

    Method of diagnosing esophageal cancer
    89.
    发明授权
    Method of diagnosing esophageal cancer 有权
    诊断食管癌的方法

    公开(公告)号：US08771963B2

    公开(公告)日：2014-07-08

    申请号：US13246639

    申请日：2011-09-27

    申请人： Yusuke Nakamura ,  Yataro Daigo ,  Shuichi Nakatsuru

    发明人： Yusuke Nakamura ,  Yataro Daigo ,  Shuichi Nakatsuru

    IPC分类号： C12Q1/00 ,  G01N1/00 ,  G01N33/53 ,  G01N33/566 ,  G01N33/567 ,  G01N33/574

    CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y10T436/25

    摘要： In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer.

    摘要翻译： 为了鉴定涉及食管癌发生的分子以及可用于诊断标志物以及新药和免疫治疗靶标的分子，构建了代表32,256个基因的cDNA微阵列，分析19例食管鳞状细胞癌（ESCCS）的表达谱 ）通过激光捕获显微切割纯化。 本文公开了在食管癌中显着上调或下调的基因组的详细全基因组数据库。 这些基因可用于治疗药物或免疫治疗以及肿瘤标志物的开发。 此外，本文公开了与淋巴结转移和手术后复发相关的基因。 在候选分子靶基因中，进一步表征ECT2，CDC45L和DKK1。 用ECT2或CDC45L的小干扰RNA（siRNA）处理ESCC细胞抑制癌细胞的生长。 因此，本文的数据提供了用于鉴定诊断系统和用于食管癌的治疗靶分子的有价值的信息。